To the best of our knowledge, these results provide the first evidence that the miR 17–92 cluster may functionally contribute to RB tumor progression and also reveal a possible novel regulatory link between the miR 17–92 cluster and human EpCAM-expressing RB tumors. Here, EPCAM is linked to neoplasm.